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Hepatocellular Carcinoma after
Transcatheter Arterial Chemoembolization:
Difficulties on Imaging Follow-up
ue to the narrow surgical indications for
hepatocellular carcinoma (HCC) in the
cirrhotic liver with decreased liver function,
transcatheter arterial chemoembolization (TACE) has been
generally performed in the worldwide institutions for the
curative or palliative treatment of this tumor. In the
majority of the cases, however, the tumors are not
completely necrotized, and the recurrence rate after TACE
is still high even for the patients who have received curative
TACE for grossly uncomplicated localized lesions (1). Thus,
on the follow-up imaging studies after TACE, accurate
diagnosis of a residual or locally recurrent tumor is crucial
and this can facilitate successful management at an early
stage of the disease so as to avoid more complicated or
advanced disease that has an unfavorable prognosis.
Multiphase dynamic CT, including the pre-contrast
phase, the arterial phase and the more delayed phase
imaging, is popularly used for evaluating the therapeutic
effect of TACE because the degree of uptake and the
distribution of the iodized oil within the tumor and the
surrounding hepatic parenchyma can provide useful
information on the degree of tumor necrosis, and so a
strategy can be planned for the subsequent therapeutic
approach (2 4). The article by Jang et al. (5) in this issue
of the Korean Journal of Radiology is one of the studies
that have assessed the diagnostic ability of multiphase
dynamic CT to depict a viable tumor in HCC treated with
TACE. In that study, a review of the previous serial CT
images provided more accurate information for the
determination of the viability of the lesion than did a
review of the last CT alone in several cases that were
roughly verified by subsequent pathological review of the
resected specimens. The overall false positive interpreta-
tion rate for the totally necrotic tumors was just 3%;
however, false negative interpretation for viable tumors
was 22%, which was still too high to get reliable results
with using the serial follow-up CT as the main diagnostic
tool. In this editorial, I discuss the issues and difficulties for
the imaging follow-up of HCC after TACE.
Focal Iodized Oil Defect in the Lesion
A focal defect in the mass having iodized oil accumula-
tion or focal washout of iodized oil during follow-up
suggests the presence of a viable tumor within the
corresponding area. However, the pre-existing tumor
necrosis within the lesions before TACE also appears as an
iodized oil defect after TACE. From this viewpoint, the
pre-TACE initial CT should be reviewed along with the
follow-up images in a side-by-side manner to determine
the nature of the iodized oil defect. Multiple serial follow-
up imaging studies are helpful to depict the interval change
of the iodized oil defect area. A long-standing non-enhanc-
ing hypoattenuating area (longer than one year) within a
HCC lesion is regarded as necrosis (5). Focal washout of
the iodized oil from the tumor suggests the presence of
collateral vessels. A careful search for the appropriate
collateral vessels should be made during any subsequent
TACE.
Partial Volume and/or Beam Hardening Artifact
Although grossly homogeneous and dense deposition of
iodized oil within lesions would indicate massive necrosis
of the tumors, the degree of iodizedoil retention and the
degree of necrotic areas sometimes differ (6). Although all
of the false negative lesions in the study of Jang et al. (5)
showed more than 90% or greater necrosis on pathologic
examination, yet the high percentage of necrosis had no
impact from the viewpoint of complete remission. The
follow-up CT of patients treated with chemoembolization
is generally affected by artifacts that are produced by high
concentrations of iodized oil, and this makes it difficult to
evaluate the enhancing characteristics of the lesion. Kubota
et al. (7) documented the feasibility of dynamic MR
imaging and power Doppler ultrasonography for the
evaluation of viable tumor that is hidden in a high density
of iodized oil on the CT scan taken at five to seven days
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after TACE. Although highly concentrated iodized oil in
the lesion shortens the T1-relaxation time, two to three
months after TACE, iodized oil does not significantly affect
the intra- and extralesional signal intensity and this has the
advantage to find a hypervascular viable focus in the area
of iodized oil accumulation (8).
Non-tumorous Arterioportal Shunt
After TACE, mechanical or chemical injury of the small
hepatic arterial branches can cause non-tumorous small
arterioportal fistula around or at a distance from the lesion
(9). A typically wedge-shaped early enhancement pattern
without any attenuation difference on the pre- and delayed
phase images could be regarded as nontumorous lesion (5);
however, structural distortion and/or inhomogeneous
attenuation of the background parenchyma that consists of
fibrosis and regeneration in the advanced cirrhotic liver
can reduce the diagnostic confidence because some of the
enhancing foci can show an irregular or nodular contour.
MR imaging using Kupffer cell agent (superparamagnetic
iron oxide particles) can be helpful to diagnose non-
tumorous arterioportal shunt (10).
Perilesional Parenchymal Inflammation, Ischemic
Injury or Infact
The iodized oil and anticancer drug emulsion directly
affects the perilesional hepatic parenchyma by causing
chemical inflammation and ischemic injury of the portal
track, and this is reversely correlated with the degree of
cirrhosis (11, 12). Embolic materials also flow into the
portal venules through the transplexal route, and this leads
to obliteration of the portal venules. In the above
conditions, the decreased arterial and portal venous
perfusion results in parenchymal infarct. Reperfusion of
previously infarcted parenchyma by collateralization of the
hepatic arterioles can show inhomogeneous arterial phase
enhancement, in addition to the low attenuation density of
the affected area on the pre-contrast CT that mimics HCC.
Although this area is seen as rather amorphous or irregu-
lar, the decreased Kupffer cell count that is due to the
substantial parenchymal injury can be misdiagnosed as
viable tumor even on MR imaging with using superpara-
magnetic iron oxide agent.
Making the correct diagnosis of viable tumor on follow-
up CT after TACE for HCC is always challenging for the
physician in their daily practice. Considering the various
factors related to the tumor itself, the embolic agent, the
perfusional variation and the adjacent parenchymal injury,
I believe that meticulous observation of the serial follow-
up CT images along with the use of other imaging modali-
ties, including MR imaging or ultrasonography with
optimized imaging protocols, if indicated, can overcome
the limitations of CT in many cases.
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